Form 4: Sage Therapeutics Director Michael Cola Granted Stock Options Under 2024 Equity Plan

Sage Therapeutics, Inc. Director Michael F. Cola was granted 21,500 stock options with an exercise price of $6.77 per share, vesting by June 2026.

Summary

• Michael F. Cola, a Director of Sage Therapeutics, Inc. (SAGE), was granted 21,500 stock options.
• The options have an exercise price of $6.77 per share.
• The transaction date for this grant was June 11, 2025.
• The options were issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan, as part of the company's Non-Employee Director Compensation Program.
• The options will vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service as a director.
• The expiration date for these stock options is June 11, 2035.
• Following this transaction, Michael F. Cola beneficially owns 21,500 derivative securities (stock options) directly.

Sentiment

Score: 6

Explanation: The document reports a standard equity grant to a director, which is generally a neutral to slightly positive event as it aligns interests, but does not contain information on company performance or significant strategic shifts.

Positives

• The grant of stock options to a director aligns management and director interests with those of shareholders, incentivizing long-term performance.
• The issuance is part of a pre-existing and approved 2024 Equity Incentive Plan and Non-Employee Director Compensation Program, indicating structured governance.

Future Outlook

The stock options granted to Director Michael F. Cola are scheduled to vest in full upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, contingent on his continued service as a director.

Management Comments

• "Brandon Marsh, as Attorney-in-Fact for Michael F Cola" (Signature on Form 4, indicating the filing was made on behalf of Mr. Cola).

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, including biotechnology and pharmaceuticals, serving as a standard component of compensation packages designed to attract, retain, and align the interests of directors with long-term shareholder value.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is a standard compensation practice in the biotechnology and pharmaceutical sectors, comparable to similar programs at companies like Biogen Inc. or Vertex Pharmaceuticals Inc., which also utilize equity-based incentives to align director interests with company performance.
• The vesting schedule, tied to continued service and a specific future date or annual meeting, is typical for such director compensation plans, ensuring retention and commitment.

Corporate Governance

Related Party Transactions

• The grant of 21,500 stock options to Michael F. Cola, a director, constitutes a related party transaction as part of his compensation under the company's Non-Employee Director Compensation Program.

Stakeholder Impact

• Shareholders: The equity grant aligns the director's financial interests with the company's long-term performance, potentially benefiting shareholders through improved governance and strategic oversight.
• Employees: While not directly impacting employees, a well-compensated and aligned board can contribute to overall company stability and strategic direction, indirectly benefiting employees.

Next Steps

• The granted stock options will vest upon the earlier of June 11, 2026, or the day immediately prior to the 2026 Annual Meeting of Sage's stockholders, subject to continued service.

Key Dates

Keywords

Sage Therapeutics, SAGE, SEC Form 4, Stock Option, Equity Incentive Plan, Director Compensation, Insider Transaction, Derivative Securities